Lite StrategyLITS -2.51%22 ROE % is -136.68% as of Mar. 2026. GuruFocus rates LITS with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,256 Biotechnology companies, Lite Strategy ranks worse than 76.91% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Lite Strategy's annualized net income for the quarter that ended in Mar. 2026 was $-94.78 Mil. Lite Strategy's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $69.34 Mil. Therefore, Lite Strategy's annualized ROE % for the quarter that ended in Mar. 2026 was -136.68%.
The historical rank and industry rank for Lite Strategy's ROE % or its related term are showing as below:
LITS'
s ROE % Range Over the Past 10 Years
Min: -106.9 Med: -64.57 Max: 61.68
Current: -105.8
During the past 13 years, Lite Strategy's highest ROE % was 61.68%. The lowest was -106.90%. And the median was -64.57%.
LITS's ROE % is ranked worse than 76.91% of 1256
companies
in the Biotechnology industry
Industry Median: -38.26
vs LITS: -105.80
Lite Strategy (NAS:LITS) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Lite Strategy ROE % Related Terms
Lite Strategy ROE % Historical Data
* Premium members only.
The historical data trend for Lite Strategy's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lite Strategy's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lite Strategy ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lite Strategy's ROE % distribution charts can be found below:
* The bar in red indicates where Lite Strategy's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Lite Strategy (LITS) has a ROE % of -136.68% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Lite Strategy and its competitors. According to the industry distribution chart, Lite Strategy ranks #966 out of 1256 companies in the Biotechnology industry, placing it in the top 76.9%.
Is Lite Strategy's ROE % too high?
Lite Strategy's current ROE % is -136.68%. Based on the distribution chart, Lite Strategy ranks #966 out of 1256 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lite Strategy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Lite Strategy's ROE % compare to DARE and ALGS?
According to the Biotechnology industry distribution chart, Lite Strategy ranks #966 out of 1256 companies for ROE %. This places Lite Strategy in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Lite Strategy and its competitors. Lite Strategy's current ROE % is -136.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lite Strategy stock overvalued right now?
Lite Strategy (LITS) has a current ROE % of -136.68%. The current ROE % is -136.68%. Lite Strategy's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Lite Strategy (LITS), the current ROE % is -136.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
22GF Score
Get the complete analysis for LITS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LITS has been successfully added to your 
